Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)

Description

This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).

Conditions

Psoriatic Arthritis

Talk to us

Study Overview

On this page

Study Details

Study overview

This will be a single-arm interventional study to test the acceptability, feasibility, and effectiveness of structured telemedicine visits to encourage lifestyle changes that will improve quality of life, disease impact, and disease activity in patients with psoriatic arthritis (PsA).

Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA): Implementation of PsOWellTM in PsA

Use of Telemedicine to Address 'Off Target' Symptoms in Psoriatic Arthritis (PsA)

Condition
Psoriatic Arthritis
Intervention / Treatment

-

Contacts and Locations

Philadelphia

University Of Pennsylvania, Philadelphia, Pennsylvania, United States, 19104

Salt Lake City

University of Utah, Salt Lake City, Utah, United States, 84112

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Population: Patients with Psoriatic Arthritis
  • * Age 18-89.
  • * Active symptoms of PsA as defined by a PsA Impact of Disease (PsAID) questionnaire score \>4 (range 0-10, 4 is the patient acceptable symptom state) or a patient global assessment of greater than 4 (scale 0-10).
  • * Patients should be stable on therapy (i.e., not planning to switch therapy at the current visit).
  • * Meet CASPAR criteria.
  • * Provision of signed and dated informed consent form.
  • * Willingness to comply with all study procedures and availability for duration of the study.
  • * Has access to a mobile phone or other mobile device.
  • * Inability to provide informed consent.
  • * Plan to change systemic treatment for psoriasis or PsA in the next 4-8 weeks.
  • * PsAID score ≤4

Ages Eligible for Study

18 Years to 89 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Pennsylvania,

Alexis Ogdie-Beatty, MD, PRINCIPAL_INVESTIGATOR, University of Pennsylvania

Study Record Dates

2025-02